Protein Kinase Inhibitors

Kinase Inhibitor

Waldenstrom Macroglobulinemia

Leukemia, Lymphocytic, Chronic, B-Cell

Lymphoma, B-Cell

Lymphoma, Mantle-Cell

<section class="Section" data-sectioncode="34089-3"><a name="section-10"></a><h1>11        DESCRIPTION</h1>Ibrutinib is a kinase inhibitor. It is a white to off-white solid with the empirical formula C25H24N6O2 and a molecular weight 440.50. Ibrutinib is freely soluble in dimethyl sulfoxide, soluble in methanol and practically insoluble in water. The chemical name for ibrutinib is 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and has the following structure:<img alt="The following structure for Ibrutinib is kinase inhibitor. It is a white to off-white solid with the empirical formula C25H24N6O2 and a molecular weight 440.50. Ibrutinib is freely soluble in dimethyl sulfoxide, soluble in methanol and practically insoluble in water. The chemical name for ibrutinib is 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4 d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and has " src="imbruvica-01.jpg"/>IMBRUVICA (ibrutinib) is available as immediate-release oral capsules, immediate-release oral tablets, and immediate-release oral suspension.IMBRUVICA (ibrutinib) capsules for oral use are available in the following dosage strengths: 70 mg and 140 mg. Each capsule contains ibrutinib (active ingredient) and the following inactive ingredients: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate. The capsule shell contains gelatin, titanium dioxide, yellow iron oxide (70 mg capsule only), and black ink.IMBRUVICA (ibrutinib) tablets for oral use are available in the following dosage strengths: 140 mg, 280 mg, and 420 mg. Each tablet contains ibrutinib (active ingredient) and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl sulfate. The film coating for each tablet contains ferrosoferric oxide (140 mg, 280 mg, and 420 mg tablets), polyvinyl alcohol, polyethylene glycol, red iron oxide (280 mg tablets), talc, titanium dioxide, and yellow iron oxide (140 mg and 420 mg tablets).IMBRUVICA (ibrutinib) oral suspension contains 70 mg/mL ibrutinib (active ingredient) and the following inactive ingredients: benzyl alcohol, citric acid monohydrate, disodium hydrogen phosphate, hypromellose, microcrystalline cellulose and carboxymethylcellulose sodium, purified water and sucralose.</section>

Imbruvica

ibrutinib

ibrutinib 140 MG Oral Capsule

ibrutinib 140 MG Oral Capsule [Imbruvica]

ibrutinib 70 MG Oral Capsule

ibrutinib 70 MG Oral Capsule [Imbruvica]

ibrutinib 140 MG Oral Tablet

ibrutinib 140 MG Oral Tablet [Imbruvica]

ibrutinib 280 MG Oral Tablet

ibrutinib 280 MG Oral Tablet [Imbruvica]

ibrutinib 420 MG Oral Tablet

ibrutinib 420 MG Oral Tablet [Imbruvica]

ibrutinib 560 MG Oral Tablet

ibrutinib 560 MG Oral Tablet [Imbruvica]

ibrutinib 70 MG/ML Oral Suspension

ibrutinib 70 MG/ML Oral Suspension [Imbruvica]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide

Pharmacy List

How To Order Imbruvica

Coverage Authorization Request 

Coverage Authorization Appeals

Imbruvica By Your Side Enrollment Form - HCP

Dose Exchange Program Form

Enroll in Patient Savings Program

Imbruvica By Your Side Support Program 

Instructions For Use (Oral Suspension): Pediatric cGVHD 

 Coding Information: Adult cGVHD

About Imbruvica: Adult cGVHD

About Imbruvia: Pediatric cGVHD

Side Effects: Adult cGVHD

Patient Resources: Adult cGVHD

Instructions For Use (Oral Suspension): Adult cGVHD

Coding Information: CLL/SLL

About Imbruvica: CLL/SLL

Side Effects: CLL/SLL

Patient Resources: CLL/SLL

Instructions For Use (Oral Suspension): CLL/SLL

Coding Information: WM

About Imbruvica: WM

Side Effects: WM

Patient Resources: WM

Instructions For Use (Oral Suspension): WM